548 related articles for article (PubMed ID: 18225585)
1. TP53 mutation in prostate needle biopsies--comparison with patients follow-up.
Ecke TH; Schlechte HH; Hübsch A; Lenk SV; Schiemenz K; Rudolph BD; Miller K
Anticancer Res; 2007; 27(6B):4143-8. PubMed ID: 18225585
[TBL] [Abstract][Full Text] [Related]
2. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens.
Pacelli A; Bostwick DG
Urology; 1997 Sep; 50(3):355-9. PubMed ID: 9301697
[TBL] [Abstract][Full Text] [Related]
4. TP53 gene mutations in prostate cancer progression.
Ecke TH; Schlechte HH; Schiemenz K; Sachs MD; Lenk SV; Rudolph BD; Loening SA
Anticancer Res; 2010 May; 30(5):1579-86. PubMed ID: 20592345
[TBL] [Abstract][Full Text] [Related]
5. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
6. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
7. p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer.
Schlechte H; Lenk SV; Löning T; Schnorr D; Rudolph BD; Ditscherlein G; Loening SA
Eur Urol; 1998; 34(5):433-40. PubMed ID: 9803007
[TBL] [Abstract][Full Text] [Related]
8. Production of serum-free and total prostate-specific antigen due to prostatic intraepithelial neoplasia.
Minardi D; Galosi AB; Dell'Atti L; Hanitzsch H; Mario P; Muzzonigro G
Scand J Urol Nephrol; 2002; 36(5):323-9. PubMed ID: 12487735
[TBL] [Abstract][Full Text] [Related]
9. Different patterns of p53 mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of microdissected specimens.
Yasunaga Y; Shin M; Fujita MQ; Nonomura N; Miki T; Okuyama A; Aozasa K
Lab Invest; 1998 Oct; 78(10):1275-9. PubMed ID: 9800953
[TBL] [Abstract][Full Text] [Related]
10. Predictors of prostate cancer on extended biopsy in patients with high-grade prostatic intraepithelial neoplasia: a multivariate analysis model.
Abdel-Khalek M; El-Baz M; Ibrahiem el-H
BJU Int; 2004 Sep; 94(4):528-33. PubMed ID: 15329106
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of transurethral resection of the prostate in "asymptomatic" patients with an elevated prostate-specific antigen level.
van Renterghem K; Van Koeveringe G; Achten R; Van Kerrebroeck P
Eur Urol; 2007 Sep; 52(3):819-26. PubMed ID: 17418482
[TBL] [Abstract][Full Text] [Related]
12. Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples.
Festuccia C; Angelucci A; Gravina GL; Muzi P; Miano R; Vicentini C; Bologna M
Int J Oncol; 2005 May; 26(5):1353-62. PubMed ID: 15809728
[TBL] [Abstract][Full Text] [Related]
13. Preneoplastic lesions of the prostate-clinical, pathological and molecular biological aspects.
Nasir A; Copeland J; Gillespie JW; Chughtai OR; Andrawis R; Kaiser HE; Manyak MJ
In Vivo; 2002; 16(6):557-66. PubMed ID: 12494901
[TBL] [Abstract][Full Text] [Related]
14. PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Ma W; Zeng G; Qi D
J Surg Oncol; 2011 Nov; 104(6):672-8. PubMed ID: 21674503
[TBL] [Abstract][Full Text] [Related]
15. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
[TBL] [Abstract][Full Text] [Related]
16. Value of prostatic cancer screening in patients treated for benign prostatic hyperplasia with medical or minimally invasive modalities.
Orihuela E; Kocurek JN; Warren MM
Arch Esp Urol; 1997 Sep; 50(7):821-4. PubMed ID: 9350090
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer antigen-1 as a potential novel marker for prostate cancer.
Liu BQ; Wu YD; Li PH; Wei JX; Zhang T; Liu RL
Asian J Androl; 2007 Nov; 9(6):821-6. PubMed ID: 17968469
[TBL] [Abstract][Full Text] [Related]
18. Do all patients with high-grade prostatic intraepithelial neoplasia on initial prostatic biopsy eventually progress to clinical prostate cancer?
Izawa JI; Lega I; Downey D; Chin JL; Luke PP
BJU Int; 2005 Aug; 96(3):320-3. PubMed ID: 16042722
[TBL] [Abstract][Full Text] [Related]
19. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer.
Kunju LP; Chinnaiyan AM; Shah RB
Histopathology; 2005 Dec; 47(6):587-96. PubMed ID: 16324196
[TBL] [Abstract][Full Text] [Related]
20. Role of transurethral biopsy sampling of the prostate to diagnose prostate cancer in men undergoing surgical intervention for benign prostatic hyperplasia.
Bales GT; Flynn TJ; Kynaston HG; Golash A; Hart A; Kim HL; Gerber GS
Tech Urol; 2000 Sep; 6(3):201-4. PubMed ID: 10963487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
